This involves finding conditions that are compatible with the highly specialised assays and coronavirus culture conditions for testing MPL. These assays and this development programme are crucial for later performing work in more advanced human airway systems.
Combining the conditions required for the specialised cell-based assays at LUMC with the highly insoluble nature and unique features of MPL, means the standard assays used for other compounds require a unique high level of optimisation in MPL testing.
Chief Scientific Officer Dr Richard Mollard said PharmAust has successfully reformulated monepantel (MPL) from a liquid product to a tablet. Part of the challenge in reformulation was addressing the poorly soluble nature of MPL in water.
PharmAust’s clinical research plans, however, remain on track. MPL manufacture in preparation for research and development in Phase 1/2 clinical trials is ongoing with trials remaining due to commence later in CY 2021
